the lead drug in Elpiscience’s bispecific macrophage engager (BiME) pipeline. Astellas has licensed rights to ES019 and a second unnamed programme and has also taken an option on up to two ...

Carisma Therapeutics is developing a unique, differentiated immuno-oncology (IO) treatment for solid tumors based on chimeric antigen receptor macrophages (CAR-M). Current IO treatments have ...

(Chairman and CEO: Darren Ji, MD, Ph.D., “Elpiscience”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced a research collaboration and license ...